BNT162b2 vaccine effectiveness was marginally affected by the SARS-CoV-2 beta variant in fully vaccinated individuals.
BNT162b2 vaccine effectiveness was marginally affected by the SARS-CoV-2 beta variant in fully vaccinated individuals.
复制标题
DOI：
10.1016/j.jclinepi.2021.10.011
复制
发表时间：
2022-03
影响因子：
7.2
通讯作者：
Huppert A
中科院分区：
文献类型：
--
作者：
Mor O;Zuckerman NS;Hazan I;Fluss R;Ash N;Ginish N;Mendelson E;Alroy-Preis S;Freedman L;Huppert A
评估辉瑞公司BNT162b2疫苗对SARS-Cov-2 β变体的有效性。以色列的大规模疫苗接种计划使用了两剂辉瑞公司的BNT162b2疫苗，成功地遏制了2020-2021年冬季甲型h1n1流感的爆发。然而，该病毒可能会发生变异，并部分逃避免疫系统。为了监测这种情况，开始对选定的感兴趣的阳性拭子样本进行测序。比较接种疫苗和未接种PCR阳性的人，我们使用逻辑回归，控制了重要的混杂因素，估计了接种疫苗的病例的β变异与α变异的比值比。在阳性样本前14天以上接种者中有19例（3.2%），未接种者中有79例（3.4%）。估计优势比为1.26 （95% CI: 0.65-2.46）。假设对α变异的有效性为95%，则对β变异的估计有效性为94% （95% CI: 88%-98%）。尽管存在对Beta变异的担忧，但BNT162b2疫苗似乎对Beta和Alpha变异都提供了实质性的免疫力。从第二次疫苗剂量后14天开始，BNT162b2疫苗的有效性受到Beta变体的最轻微影响。
To evaluate the effectiveness of the Pfizer BNT162b2 vaccine against the SARS-Cov-2 Beta variant. Israel's mass vaccination program, using two doses of the Pfizer BNT162b2 vaccine, successfully curtailed the Alpha variant outbreak during winter 2020–2021, However, the virus may mutate and partially evade the immune system. To monitor this, sequencing of selected positive swab samples of interest was initiated. Comparing vaccinated with unvaccinated PCR positive persons, we estimated the odds ratio for a vaccinated case to have the Beta vs. the Alpha variant, using logistic regression, controlling for important confounders. There were 19 cases of Beta variant (3.2%) among those vaccinated more than 14 days before the positive sample and 79 (3.4%) among the unvaccinated. The estimated odds ratio was 1.26 (95% CI: 0.65–2.46). Assuming the effectiveness against the Alpha variant to be 95%, the estimated effectiveness against the Beta variant was 94% (95% CI: 88%–98%). Despite concerns over the Beta variant, the BNT162b2 vaccine seemed to provide substantial immunity against both the Beta and the Alpha variants. From 14 days following the second vaccine dose, the effectiveness of BNT162b2 vaccine was at most marginally affected by the Beta variant.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
64.8
作者：
通讯作者：
--
DOI：
10.1016/s0140-6736(21)00947-8
发表时间：
2021-05-15
期刊：
Lancet (London, England)
影响因子：
--
作者：
Haas EJ;Angulo FJ;McLaughlin JM;Anis E;Singer SR;Khan F;Brooks N;Smaja M;Mircus G;Pan K;Southern J;Swerdlow DL;Jodar L;Levy Y;Alroy-Preis S
通讯作者：
Alroy-Preis S
DOI：
10.2807/1560-7917.es.2021.26.26.2100557
发表时间：
2021-07
期刊：
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
影响因子：
--
作者：
Lustig Y;Zuckerman N;Nemet I;Atari N;Kliker L;Regev-Yochay G;Sapir E;Mor O;Alroy-Preis S;Mendelson E;Mandelboim M
通讯作者：
Mandelboim M
影响因子：
64.8
作者：
通讯作者：
--